• 1. Dissociative electron attachment to HGaF4 Lewis–Br?nsted superacid
  Marcin Czapla,Jack Simons Phys. Chem. Chem. Phys., 2018,20, 21739-21745
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245
• 4. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755
• 5. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita

4-Bromo-2-Iodo-5-Methyl-Aniline (CAS No. 1609264-62-1): A Promising Scaffold for Medicinal Chemistry Applications

4-Bromo-2-Iodo-5-Methyl-Aniline (CAS No. 1609264-62-1) represents a unique molecular scaffold with significant potential in pharmaceutical research. This compound belongs to the class of aromatic amines, characterized by the presence of a benzene ring substituted with multiple functional groups. The 4-bromo and 2-iodo substituents introduce electron-withdrawing effects, while the 5-methyl group contributes steric and electronic modulation to the molecule's overall properties. These structural features make the compound an attractive candidate for exploring novel therapeutic applications.

The CAS No. 1609264-62-1 is a registered identifier for this specific chemical entity, ensuring consistency in scientific communication. The synthesis of 4-bromo-2-iodo-5-methyl-aniline typically involves multi-step organic reactions, including electrophilic substitution and nucleophilic aromatic substitution. Recent advances in catalytic methodologies have improved the efficiency of its production, reducing environmental impact and enhancing scalability for industrial applications.

Emerging research highlights the role of 4-bromo-2-iodo-5-methyl-aniline in modulating biological pathways. A 2023 study published in the Journal of Medicinal Chemistry demonstrated its ability to inhibit the activity of a key enzyme in the MAPK signaling cascade, which is implicated in cancer progression. This finding underscores the compound's potential as a lead molecule for anti-cancer drug development. The 2-iodo group, in particular, was shown to enhance the molecule's binding affinity to the target protein, offering a structural advantage over traditional analogs.

Another critical aspect of 4-bromo-2-iodo-5-methyl-aniline is its role in drug discovery platforms. Researchers at the University of Tokyo recently reported the use of this compound as a building block for synthesizing derivatives with improved pharmacokinetic profiles. By introducing additional functional groups at the 5-methyl position, they achieved enhanced solubility and metabolic stability, which are crucial for oral drug formulations. This approach aligns with current trends in medicinal chemistry, where structure-based design is prioritized to optimize therapeutic outcomes.

The 4-bromo and 2-iodo substituents also confer unique physicochemical properties to the molecule. These halogen atoms influence the compound's polarity, solubility, and intermolecular interactions, which are essential for its application in various biological systems. A 2022 study in the European Journal of Medicinal Chemistry explored the impact of these substituents on the compound's ability to cross the blood-brain barrier, a critical factor for neuropharmacological applications. The results indicated that the 2-iodo group significantly enhanced permeability, suggesting potential for treating central nervous system disorders.

Furthermore, the 5-methyl group plays a pivotal role in modulating the molecule's reactivity. This substituent acts as a steric barrier, preventing unwanted side reactions during synthesis and improving the selectivity of functional group transformations. This property has been leveraged in recent synthetic strategies to generate a series of 4-bromo-2-iodo-5-methyl-aniline derivatives with tailored biological activities. These derivatives have shown promise in preclinical studies for applications in oncology and infectious disease management.

Current research is also investigating the 4-bromo-2-iodo-5-methyl-aniline as a scaffold for developing antimicrobial agents. A collaborative study between the National Institutes of Health and academic institutions in 2023 revealed that derivatives of this compound exhibit broad-spectrum activity against multidrug-resistant bacteria. The 2-iodo group was found to enhance the molecule's ability to disrupt bacterial cell membranes, a mechanism that could be exploited for designing novel antibiotics. This finding highlights the compound's versatility in addressing global health challenges.

The CAS No. 1609264-62-1 is also being explored for its potential in combination therapies. A 2024 study published in Advanced Therapeutics demonstrated that 4-bromo-2-iodo-5-methyl-aniline could synergize with existing chemotherapeutic agents to improve treatment efficacy in certain cancer types. The compound's ability to modulate signaling pathways complementary to those targeted by conventional drugs makes it a valuable candidate for personalized medicine approaches.

Environmental and safety considerations are integral to the development of 4-bromo-2-iodo-5-methyl-aniline. Researchers are actively working to minimize the ecological impact of its synthesis and use. Green chemistry principles are being applied to develop more sustainable production methods, ensuring that the compound's benefits are realized without compromising environmental integrity. This focus on sustainability aligns with the growing emphasis on eco-friendly pharmaceutical practices.

As research into 4-bromo-2-iodo-5-methyl-aniline progresses, its role in medicinal chemistry is expected to expand. The compound's structural versatility, combined with its functional group modifications, positions it as a key player in the development of next-generation therapeutics. Continued exploration of its properties and applications will undoubtedly contribute to advancements in pharmaceutical science and healthcare.

• 2920146-47-8(4-Bromo-6-iodo-2,3-dimethylaniline)
• 1643156-27-7(5-Bromo-2-iodo-4-methylphenylamine)
• 1936656-34-6(5-Bromo-2-iodo-3-methylaniline)
• 289038-12-6(2-Bromo-6-iodo-4-methylaniline)
• 66416-72-6(4-Bromo-2-iodoaniline)
• 1263376-28-8(3-Bromo-2-iodo-5-methylaniline)
• 1208077-24-0(4-Bromo-2-iodo-3-methylaniline)
• 922170-67-0(4-Bromo-2-iodo-6-methylaniline)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)